Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Cagrilintide Dosing Guide
Primary Benefits
- Potent appetite suppression via amylin receptors
- Delayed gastric emptying for prolonged satiety
- Enhanced weight loss when combined with GLP-1 agonists
- Improved glucose tolerance and insulin sensitivity
- Reduced food intake and meal size
How It Works
Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.
Quick Reference
Typical Dosage Range
Clinical protocols typically begin with 0.3 mg weekly for 4 weeks, followed by gradual escalation to 0.6 mg, 1.2 mg, 1.8 mg, and maximum 2.4 mg weekly at 4-week intervals. For combination therapy (CagriSema), cagrilintide is typically dosed at 1.2-2.4 mg weekly alongside semaglutide 1.0-2.4 mg weekly. Dose escalation should be individualized based on tolerability and weight loss response.
Administration Methods
Subcutaneous injection using pre-filled pens or vials with insulin syringes. Injection sites include abdomen, thigh, or upper arm, with site rotation to prevent lipodystrophy. Administer on the same day each week, preferably at the same time. Can be taken with or without food. If a dose is missed, administer as soon as possible within 3 days, otherwise skip and resume regular schedule. When used in combination with semaglutide, separate injection sites are recommended.
What It's Used For
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Weight Management
Advanced appetite suppression through amylin pathway activation for significant weight loss
Combination Therapy
Works synergistically with semaglutide in CagriSema for enhanced weight loss results
Metabolic Health
Improves glucose tolerance and insulin sensitivity for better metabolic function
How Much to Take
Dose Escalation Protocol
CagriSema Combination
Advanced Protocol
Combined with semaglutide for enhanced weight loss (15-25% reduction)
Dual Pathway Action
Works on both amylin and GLP-1 pathways for superior appetite control
Frequency
Once weekly injection
Timing
Same day each week
Adjustment
Based on tolerance
How Long to Use It
Cagrilintide is designed for long-term weight management with sustained appetite suppression. Clinical trials have studied treatment periods of 26-68 weeks with continued effectiveness. The medication requires ongoing use to maintain weight loss benefits, as discontinuation typically leads to weight regain.
Important Research Status
Cagrilintide is currently in Phase 3 clinical trials and is not yet commercially available. Access may be limited to clinical trial participation through research centers.
Need-to-Know Information
How It Works
Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.
Key Benefits
Who Should Avoid
- Severe gastroparesis or gastric emptying disorders
- Known hypersensitivity to cagrilintide
- Active inflammatory bowel disease
- History of severe pancreatitis
Common Side Effects
- Nausea (most common, transient)
- Vomiting and gastrointestinal upset
- Decreased appetite (therapeutic effect)
- Injection site reactions
Storage & Injection
Storage Requirements
Refrigerated storage required. Store at 36-46°F (2-8°C). Protect from light.
Shelf Life
7-day half-life allows flexible weekly dosing. Can be stored at room temperature for up to 4 weeks once in use.
Injection Sites
Abdomen, thigh, upper arm
Method
Subcutaneous injection
Rotation
Weekly site rotation
Example Schedule
16-Week Dose Escalation Protocol
Month 1
0.3 mg weekly
Month 2
0.6 mg weekly
Month 3
1.2 mg weekly
Month 4+
2.4 mg weekly
Missed Dose Protocol
If you miss your weekly injection, take it as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and continue with your regular schedule. Never double dose.
Extra Tips for Best Results
Lifestyle Support
Combine with reduced-calorie diet and regular exercise for optimal weight loss results
Monitor Progress
Track weight, measurements, and side effects weekly during dose escalation
Medical Support
Work closely with healthcare provider for dose adjustments and side effect management
Side Effect Management
Eat smaller meals, stay hydrated, and increase fiber intake to minimize GI side effects
Expected Results Timeline
Clinical trials show 8-15% weight loss with monotherapy over 26 weeks, and 15-25% weight loss with CagriSema combination therapy. Maximum benefits typically seen after reaching maintenance dose at week 16.
Research Phase Medication
Cagrilintide is currently in Phase 3 clinical trials and requires medical supervision. Access is typically limited to clinical trial participation or specialized research centers.
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.